The ISN Holds First Consensus Meeting on Guidance for Optimal Pre-clinical Animal Studies in Translational Nephrology (TRANSFORM)
The ISN’s TRANSFORM meeting (TRAnslational Nephrology Science FOR new Medications) took place in Brussels, Belgium, from October 8-9, 2022.
The meeting gathered patients, clinical and academic researchers, regulators, and industry partners to:
- Report ISN Research Working Group activities describing the current landscape and future possibilities.
- Reach consensus on guidance that optimizes animal study design and drives the discovery of new drugs.
- Provide a platform for patients, clinical researchers, regulators, and industry partners to collaborate.
Recommended guidance will shortly be published for the international kidney care community.
The meeting was supported by several organizations (in alphabetical order): Astra Zeneca, Aurinia Pharma, Daiichi Sankyo, Kyowa Kirin, Otsuka Pharmaceutical Co. Ltd., Travere Therapeutics, and VisitBrussels.
